Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Wolf, Christian ^a   Sidhu, Jagdev ^b   Otoul, Christian ^c   Morris, Dexter L ^c   Cnops, Jennifer ^d   Taubel, Jorg ^e   Bennett, Barbara ^f  

^a Clinical Development   (Belgium)

^b CSL LIMITED   (Australia)

^c UCB PHARMA   (Belgium)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e Richmond Pharmacolgy   (United Kingdom)

^f BABennett Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; PLACEBO; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4; ZAURATEGRAST; PHENYLALANINE;

ABORTION; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BACKACHE; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG FATALITY; DYSPHONIA; EXPANDED DISABILITY STATUS SCALE; FALLING; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HALLUCINATION; HEADACHE; HEART PALPITATION; HEMATOPOIETIC STEM CELL; HERPES SIMPLEX; HUMAN; HYPOALGESIA; LIMB PAIN; LIVER FUNCTION TEST; LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MONOCYTE; MULTIPLE SCLEROSIS; MUSCLE SPASM; MUSCLE WEAKNESS; NATURAL KILLER CELL; OPPORTUNISTIC INFECTION; PARALLEL DESIGN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN BINDING; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; RELAPSE; SIDE EFFECT; SORE THROAT; T LYMPHOCYTE; TREATMENT DURATION; UNITED KINGDOM; UNWANTED PREGNANCY; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; FLOW CYTOMETRY; METABOLISM; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOW CYTOMETRY; HUMANS; INTEGRIN ALPHA4; INTEGRIN ALPHA4BETA1; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHENYLALANINE; RECURRENCE; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84874616871     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058438     Document Type: Article

References (29)

1. Stadelmann C, Wegner C, Brück W, (2011) Inflammation, demyelination, and degeneration-recent insights from MS pathology. Biochim Biophys Acta 1812: 275-282.
2. Ferguson TA, Mizutani H, Kupper TS, (1991) Two integrin-binding peptides abrogate T cell-mediated immune responses in vivo. Proc Natl Acad Sci U S A 88: 8072-8076.
3. Chan PY, Aruffo A, (1993) VLA-4 integrin mediates lymphocyte migration on the inducible endothelial cell ligand VCAM-1 and the extracellular matrix ligand fibronectin. J Biol Chem 268: 24655-24664.
4. D'hooghe MB, Nagels G, Bissay V, De Keyser J, (2010) Modifiable factors influencing relapses and disability in multiple sclerosis. Mult Scler 16: 773-785.
5. Müller WA, (2011) Mechanisms of leukocyte transendothelial migration. Annu Rev Pathol 6: 323-344.
6. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, et al. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356: 63-66.
7. Soilu-Hanninen M, Roytta M, Salmi A, Salonen R, (1997) Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis. J Neuroimmunol 72: 95-105.
8. Lee SJ, Benveniste EN, (1999) Adhesion molecule expression and regulation on cells of the central nervous system. J Neuroimmunol 98: 77-88.
9. Davenport RJ, Munday JR, (2007) Alpha4-integrin antagonism-an effective approach for the treatment of inflammatory diseases? Drug Discov Today 12: 569-576.
10. Polman CH, O'Connor PW, Havrdová E, Hutchinson M, Kappos L, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.
11. Kent SJ, Karlik SJ, Cannon C, Hines DK, Yednock TA, et al. (1995) A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 58: 1-10.
12. Rudick RA, Sandrock A, (2004) Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 4: 571-580.
13. Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, et al. (2010) Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci 292: 28-35.
14. Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, et al. (2008) Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist. Bioorg Med Chem 16: 9991-10000.
15. Kenyon NJ, Liu R, O'Roark EM, Huang W, Peng L, et al. (2009) An alpha4beta1 integrin antagonist decreases airway inflammation in ovalbumin-exposed mice. Eur J Pharmacol 603: 138-146.
16. Vanderslice P, Woodside DG, Caivano AR, Decker ER, Munsch CL, et al. (2010) Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin alpha4beta1. Biochem Biophys Res Commun 400: 619-624.
17. Baker M, Shock A, Parton T, Hales P, Parker G, (2006) Pharmacokinetic and pharmacodynamic properties of the VLA-4 inhibitor CDP323. Mult Scler 12: S106.
18. Miller D, Khan O, Sheremata W, Blumhardt L, Rice G, et al. (2001) Results of a double-blind, randomized, placebo-controlled, phase II trial of Antegren (natalizumab) in subjects with relapsing multiple sclerosis (MS). Mult Scler 7: S16.
19. Polman C, Bowen J, Barkhof F, Bates D, Wynn D, et al. (2010) Double-blind, placebo-controlled, randomized phase II serial MRI, safety and tolerability study of two doses of CDP323 in subjects with relapsing forms of multiple sclerosis over 24 weeks. Presented at the 62nd Annual Meeting of the American Academy of Neurology, Toronto, Canada.
20. Kong L, Koch G, Liu T, Wang H, (2005) Performance of some multiple testing procedures to compare three doses of a test drug and placebo. Pharmaceut. Statist. 4: 25-35.
21. Kovarik JM, Schmouder R, Barilla D, Riviere GJ, Wang Y, et al. (2004) Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 44: 532-537.
22. Niino M, Bodner C, Simard ML, Alatab S, Gano D, et al. (2006) Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 59: 748-754.
23. Krumbholz M, Meinl I, Kumpfel T, Hohlfeld R, Meinl E, (2008) Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 71: 1350-1354.
24. Putzki N, Baranwal MK, Tettenborn B, Limmroth V, Kreuzfelder E, (2010) Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. Eur Neurol 63: 311-317.
25. Lichterfeld M, Martin S, Burkly L, Haas R, Kronenwett R, (2000) Mobilization of CD34+ haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4. Br J Haematol 110: 71-81.
26. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, et al. (2008) The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 111: 3893-3895.
27. Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T, (2008) Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 111: 3439-3441.
28. Jing D, Oelschlaegel U, Ordemann R, Holig K, Ehninger G, et al. (2010) CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant 45: 1489-1496.
29. Neumann F, Zohren F, Haas R, (2009) The role of natalizumab in hematopoietic stem cell mobilization. Expert Opin Biol Ther 9: 1099-1106.